CareDx (CDNA) Stock Price Up 9%
Shares of CareDx Inc (NASDAQ:CDNA) rose 9% during trading on Tuesday . The stock traded as high as $23.95 and last traded at $23.84. Approximately 999,248 shares were traded during mid-day trading, an increase of 88% from the average daily volume of 530,293 shares. The stock had previously closed at $21.87.
CDNA has been the topic of several research analyst reports. HC Wainwright set a $17.00 price objective on CareDx and gave the company a “hold” rating in a report on Friday, August 10th. Craig Hallum set a $35.00 price target on CareDx and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. Piper Jaffray Companies lifted their price target on CareDx to $42.00 in a research note on Wednesday, September 5th. Zacks Investment Research raised CareDx from a “sell” rating to a “hold” rating in a research note on Monday, August 27th. Finally, BidaskClub lowered CareDx from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $28.25.
The company has a debt-to-equity ratio of 0.46, a current ratio of 2.16 and a quick ratio of 1.83. The company has a market capitalization of $1.05 billion, a PE ratio of -33.09 and a beta of 0.92.
In related news, insider Sasha King sold 9,458 shares of CareDx stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $14.03, for a total transaction of $132,695.74. Following the transaction, the insider now owns 71,792 shares in the company, valued at $1,007,241.76. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Michael Brian Bell sold 12,500 shares of CareDx stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $16.84, for a total value of $210,500.00. Following the transaction, the chief financial officer now owns 68,593 shares in the company, valued at approximately $1,155,106.12. The disclosure for this sale can be found here. Insiders sold 64,813 shares of company stock worth $1,382,452 over the last ninety days. Corporate insiders own 3.40% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. CAPROCK Group Inc. purchased a new position in CareDx during the third quarter worth approximately $237,000. Northern Trust Corp lifted its position in CareDx by 737.0% during the second quarter. Northern Trust Corp now owns 369,484 shares of the company’s stock worth $4,523,000 after buying an additional 325,341 shares in the last quarter. Bank of New York Mellon Corp lifted its position in CareDx by 128.8% during the second quarter. Bank of New York Mellon Corp now owns 155,802 shares of the company’s stock worth $1,907,000 after buying an additional 87,698 shares in the last quarter. Casdin Capital LLC purchased a new position in CareDx during the second quarter worth approximately $2,448,000. Finally, Millennium Management LLC lifted its position in CareDx by 51.5% during the second quarter. Millennium Management LLC now owns 242,613 shares of the company’s stock worth $2,970,000 after buying an additional 82,461 shares in the last quarter. Hedge funds and other institutional investors own 72.88% of the company’s stock.
CareDx Company Profile (NASDAQ:CDNA)
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
See Also: What Does Beta Mean In Stock Selection
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.